STOCKHOLM, SWEDEN, - October 27, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a recently published article in the journal "Molecular Psychiatry", a part of Nature, named "Ectodermal origins of the skin-brain axis: a novel model for the developing brain, inflammation, and neurodevelopmental conditions" discusses that EIS may represent an alternate clinical measure of skin barrier integrity that may function as a surrogate for neurodevelopmental divergence.
The article describes Electrical impedance spectroscopy (EIS) as a recently emerged promising alternative measurement of skin barrier function. EIS is a non-invasive indicator of epidermal integrity, rapidly measuring the skin's resistance to the flow of alternating imperceptible currents. Considering the likely differences in cell size and orientation between typical and abnormal skin, EIS has been suggested as a useful proxy for disease status. Currently, EIS has been observed to successfully differentiate between healthy, lesional and non-lesional skin in adults with AD, with these readings inversely correlating to TEWL.
In the article the authors hypothesize: "In this paper, we propose a novel hypothesis, that there is an antenatal link between skin and neurodevelopment, partially underpinned by the tissue's shared ectodermal origin with common molecular factors. Additionally, we evaluate postnatal mediators of this skin-brain co-vulnerability, considering the role of epidermal keratinocytes and the cutaneous microbiota in cortical development. Accordingly, we hypothesize that skin barrier integrity may represent an accessible and novel biomarker to aid in the early detection of neurodevelopmental divergence. We further propose that skin barrier integrity may play a crucial role in mediating the relationship between environmental triggers of infection, immune processes, and neurodevelopment, with potential to reduce the impact of such environmental triggers by improving skin barrier integrity".
The article is available through the following link:
"This study shows the increasing interest in EIS and Nevisense and that it can become a very useful clinical measure in the management of different diseases when looking at skin barrier integrity. Previous studies have already shown that Nevisense can discriminate between patients with and without atopic dermatitis through non-lesional skin measurements and this has created the basis for the interest we see as EIS has the potential to track improvement after therapy. We believe that Nevisense and EIS have the potential to become a standard of care in this space and a very significant opportunity for SciBase", says Simon Grant, CEO of SciBase.
For more information, please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
November 7, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has signed an agreement with Johnson & Johnson Consumer Inc. to collaborate on the development of a unique AI-based screening tool to predict the development of a common type of eczema called atopic dermatitis in infants.
The goal of the collaboration is to develop and validate an AI-based solution that detects skin barrier dysfunction and may be able to predict an infant’s risk of developing atopic dermatitis. The method will be based on SciBase’s Electrical Impedance Spectroscopy (EIS) technology and specifically for the portable Nevisense Go device.
The collaboration will start immediately and will run for two years and includes supporting a study at several hospitals in Switzerland with Dr Caroline Roduit as Principal Investigator. Dr Roduit commented:
‘’I work every day with the management of different allergic diseases in children, and it is a growing problem. Allergic diseases have a natural progression with atopic dermatitis being the first to manifest, often already in infancy, followed by other allergic diseases, such as food allergy and allergic asthma. The ability to identify these children early, will help to develop preventive strategies for allergic diseases, and Nevisense is an extremely promising method that has potential for early prediction of those children.”
Skin barrier assessment is a new application for SciBase’s EIS technology and this collaboration represents one of the three most promising new clinical indications.
“This project is a milestone for SciBase. It is our vision that Nevisense Go will become the standard of care for this indication. Twenty percent of children develop atopic dermatitis and the ability to predict which children are at high risk could significantly expand the development and use of prophylactic treatments.
The promise of the test is that it is non-invasive and can be used widely - in this study the test will be performed using Nevisense Go in the home of the infant. If successful, the combination of ease and unique predictive information of the test could translate into broad adoption and open a significant consumer market for SciBase. We see the collaboration as an important step in shaping a future where medical technology is accessible, non-invasive, and personalized.”, says Simon Grant CEO SciBase.
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 16.30 CET on November 7, 2022.
For more information, please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
STOCKHOLM, SWEDEN - November 8, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced on Monday November 7 that it has initiated a collaboration with Johnson & Johnson Consumer Health Inc. to develop a unique AI-based screening tool to predict the development of a common type of eczema called atopic dermatitis in infants.
Link to press release from November 7th: http://investors.scibase.se/en/scibase-announces-collaboration-to-detect-skin-barrier-dysfunction-in-infants
Simon Grant, CEO of SciBase comment on the skin barrier segment and the collaboration with Johnson & Johnson Consumer Health Inc. can be found through the link below:
Link to CEO comment
For more information around skin barrier and SciBase: https://barrier.scibase.com/
For more information, please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
STOCKHOLM, SWEDEN - November 8, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders is pleased to invite investors, analysts and media to a webinar on November 10 at CET 11.00 - 12.00. The event will only be digital.
The focus will be on SciBase's recently announced collaboration with Johnson & Johnson Consumer Health to develop a unique AI-based screening tool to predict the development of a common type of eczema known as atopic dermatitis in infants. SciBase CEO Simon Grant will give an in-depth picture of the potential that exists in the skin barrier segment as well as a general update.
Link to the webinar: https://us06web.zoom.us/webinar/register/WN__tjnmigWSDeqGmY4LYbnRg
Agenda for the webinar:
Introduction by CEO Simon Grant
Background around skin barrier from Professor Cezmi Akdis
Presentation by CEO Simon Grant
Q&A
The webinar will be held in English. Participants will be given the opportunity to ask questions during the event via chat. Questions can also be submitted in advance to [email protected].
A recorded version of the webinar will be available on the SciBase website afterwards.
For more information around skin barrier and SciBase: https://barrier.scibase.com/
For more information, please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
STOCKHOLM, SWEDEN, - September 1, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today scientific results that demonstrate the detrimental effects that common detergents can have on the health of the skin barrier. Top line results were presented recently at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland. The study, which is not yet published, was performed by SIAF (CH), CK-CARE (CH), SciBase (SE) and the Sean N. Parker Allergy and Asthma research institute at Stanford (US). The study demonstrates that household laundry detergents disrupt the skin barrier integrity in mice.
The use of professional and household cleaning agents is associated with an increased risk of developing allergic disorders. In line with this, impairment of the epithelial barrier is also associated with the development of allergic disorders.
The aim of the study was to utilize Nevisense and Electrical Impedance Spectroscopy (EIS) to assess the effect of commercially available detergents on the skin barrier of mice. The top line results of the study indicated that:
Even at very low concentrations household detergents can impact the epidermis integrity, leading to an impaired skin barrier.
Prolonged exposure to detergent residue in clothes could progressively impair the barrier, leading to a higher risk of allergen sensitization.
Detergents could also aggravate already existing allergic disorders such as atopic dermatitis, increasing disease severity.
EIS is a fast and reliable tool for in vivo detection of barrier function with possible applications in dermatological and cosmetic studies.
"Since the 1960's we have seen a pandemic-scale increase in the prevalence of allergic diseases, affecting one billion individuals. This study highlights the risk that laundry detergents are contributing to this development, as further described in our "epithelial barrier hypothesis". We are very encouraged to see that EIS measurements could identify skin barrier impairment at such an early stage and at such low detergent concentrations. EIS provides an increasingly useful tool for such evaluations" said Professor Cezmi Akdis at SIAF (Swiss Institute of Asthma and Allergy Research).
"This is a fascinating study that shows the negative effect of common household detergents on the skin barrier, and though a mouse study, there are clearly implications for the general population. Skin barrier integrity is an important factor in many allergic diseases and EIS measurements of the skin barrier can provide unique and valuable insights in the prevention and management of these diseases. Studies have already shown that Nevisense can discriminate between patients with and without atopic dermatitis through non-lesional skin measurements and has the potential to track improvement after therapy. We believe that Nevisense and EIS have the potential to become a standard of care in this space and a very significant opportunity for SciBase.", says Simon Grant CEO SciBase.
For more information, please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on May 18, 2022.
The Annual General Meeting of SciBase Holding AB (publ) will be held on May 18, 2023 in Stockholm.
Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.
Stockholm, October 7, 2022
SciBase Holding AB (publ)
For more information, please contact: Tord Lendau, Chairmain of the board, phone +46 (0)70 810 01 67
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
STOCKHOLM, SWEDEN, - October 26, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new clinical study has been published presenting the improvement that the Nevisense test provides over standard of care visual and dermoscopic evaluation. The article named "Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy" has been published in the journal "Melanoma Research". The study included 231 US Dermatologists making a total of 33.957 biopsy decisions. The study participants showed a statistically significant improvement in correct biopsy decisions beyond their dermoscopic evaluation when integrating the Nevisense result. With Nevisense, Dermatologists identified more melanomas for biopsy; their sensitivity increasing from 85.2% to 91.1%.
The article is available through the following link: https://journals.lww.com/melanomaresearch/Abstract/9900/Electrical_impedance_spectroscopy_significantly.42.aspx
Prof Darrell Rigel, Icahn School of Medicine at Mount Sinai, New York and author of the study commented: "The overall findings from this study demonstrate that the integration of EIS technology into PSL biopsy decisions has the potential to significantly improve the accuracy of lesion selection for biopsy beyond clinical and dermoscopic evaluation alone."
"This is a very important study and result for SciBase as it quantifies the improvement in clinical decision-making possible with Nevisense compared to visual methods that are today considered the standard of care. As expected, the study showed that dermoscopy improved decision making over naked eye assessment, but more importantly it showed that using Nevisense further improved clinician performance by at least as much again. Adding Nevisense clearly resulted in the best clinical management decisions. This is one of several publications that shows that Nevisense has a significant role in the challenging process for clinicians to identify malignancies", says Simon Grant, CEO of SciBase.
For more information, please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
Today, the annual general meeting of 2022 was held in SciBase Holding AB (publ) (the "Company" or "SciBase"). Below follows a summary of the resolutions passed at the annual general meeting.
The annual general meeting resolved:
to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2021;
that SEK 202,229,730 shall be carried forward in new account and that no dividend shall be paid;
to grant the board members and the CEO discharge from liability for the financial year 2021;
that the board of directors shall consist of five ordinary members without deputy members and that a registered accounting firm shall be elected as auditor;
that the fees payable to the board of directors for the period until the end of the next annual general meeting shall be SEK 200,000 for the chairman of the board and SEK 150,000 to each of the other ordinary board members (who are not employed by a larger shareholder in the Company) and that fees payable to the auditor is to be paid in accordance with approved invoices;
for the period until the end of the next annual general meeting, to re-elect Jvalini Dwarkasing, Diana Ferro, Matt Leavitt, Thomas Taapken and Tord Lendau as board members, to re-elect Tord Lendau as chairman of the board of directors and to re-elect the auditing firm PricewaterhouseCoopers AB (PwC) as auditor for the Company, with Magnus Lagerberg as auditor-in-charge;
to adopt principles for the appointment of a nomination committee (same principles as previous year); and
to authorize the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures. New issues of shares and issues of warrants and/or convertibles may occur with or without preferential rights for shareholders of the Company and may be made either in cash and/or by way of set-off or contribution in kind or otherwise be conditional. Through issuances resolved upon with support from the authorization – with deviation from the shareholders’ preferential rights - the number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall correspond to not more than a 20 per cent dilution of the share capital and the number of shares and votes in the Company after such issue(s).
For more information, please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
The information was submitted, through the agency of the contact person set out above, for publication at the time stated by SciBase's news distributor Cision upon publication of this press release.
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.
STOCKHOLM, SWEDEN, - August 9, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that the FDA (US Food and Drug Administration) held a meeting with the Medical Devices Advisory Committee on July 28th and 29th to gather expert advice on the regulation of AI driven, skin lesion analyzers (SLAs) and Apps for skin cancer detection.
Panel members urged caution for skin cancer detection SLAs and Apps and stressed the need for more high quality research to validate these technologies. "The standards would have to be set very high for new products, especially those intended for consumers," said FDA panelist Murad Alam, MD, a dermatologist from Northwestern University, Chicago, Illinois.
The panel also considered the FDA's proposal to change the classification status of Nevisense and any new products that assist dermatologists in melanoma detection from the most stringent regulatory category, class III, to the less restrictive class II. The Panel underscored the potential risks of reclassifying these technologies and strongly recommended keeping them in the class III category. SciBase shared the same opinion as panel experts through written submissions and oral presentations. SciBase believes the current process where FDA sets very high standards and is closely involved in clinical validation study design is the most appropriate.
"We very much agree with the Panel's recommendation. Nevisense is currently the only SLA available on the market and we have gone through the very rigorous Class III PMA (Pre Market Approval) process with it's extremely high safety demands. Reclassifying this type of product to Class II would reduce the level of FDA oversight for new products entering into this space; something we believe could potentially compromise patient safety.
While the FDA is not legally bound to follow the Panel's recommendation, we believe that such an overwhelming recommendation will be difficult for the FDA to ignore. A final decision from FDA could take months or years, though it is our belief that even in the medium term a decision would not practically affect Nevisense or the market itself as stringent requirements on clinical study data would still apply.", says Simon Grant CEO SciBase.
For more information, please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.
The loss after tax amounted to TSEK 9,212 (11,151).
The loss per share amounted to SEK 0.13 (0.19).
The cash flow from current operations was negative in the amount of TSEK 9,643 (9,162).
The gross margin reached 70,6% (56.3%).
Electrode sales volume increased by 60% and reached 9,550 (5,968) units. Repeat sales of electrodes to existing customers increased by 58%.
January - June in figures
Net sales amounted to TSEK 7,987 (4,821), +66%.
The loss after tax amounted to TSEK 18,948 (19,304).
The loss per share amounted to SEK 0.28 (0.34).
The cash flow from current operations was negative in the amount of TSEK 20,155 (18,635).
The gross margin reached 66,4% (54.4%).
Electrode sales volume increased by 45% and reached 19,580 (13,464) units. Repeat sales of electrodes to existing customers increased by 45%.
Important events during the quarter
Overall sales increased by 65% (+56%, before currency effects). The sales in the important US market increased within the area of skin cancer by 146% (in local currency by 104%). Sales in Germany increased by 54% (49% in local currency).
A new study performed in Germany and published online in the journal Dermato demonstrated the clinical benefits of Nevisense in day-to-day practice.
A new study published in the US demonstrated that EIS and Nevisense can significantly improve clinical decisions in the dermatology day-to-day practice, especially for less experienced clinicians. The study titled – “Diagnostic Efficacy Of Electrical Impedance Spectroscopy Versus Dermoscopy For Pigmented Skin Lesions: A Pilot Study” and authored by Dr Jonathan Ungar, Associate Director and Assistant Professor, Dermatology Department, et al at Icahn School of Medicine at Mount Sinai, New York, was published online in “SKIN-The Journal of Cutaneous medicine”.
The annual report for 2021 was published.
The AGM 2022 was held on May 18, 2022.
Important events after the end of the period
FDA expert panel in line with SciBase position to keep stringent approval level for all new skin lesion analyzers.
Financial overview
July 1 2021 -
Apr 1 - June 30
Jan 1 - June 30
June 30 2022
Jan 1 - Dec 31
THE GROUP
2022
2021
2022
2021
Rolling-12
2021
Net sales, SEK ths
3 726
2 258
7 987
4 821
14 893
11 727
Gross margin, %
70,6%
56,3%
66,4%
54,4%
62,2%
56,1%
Equity/Asset ratio, %
76,6%
87,3%
76,6%
87,3%
83,3%
82,8%
Net indebtness, multiple
0,30
0,15
0,30
0,15
0,20
0,21
Cash equivalents, SEK ths
44 577
88 192
44 577
88 192
44 577
65 607
Cashflow from operating activities, SEK ths
-9 643
-9 162
-20 155
-18 635
-41 021
-39 501
Earnings per share (before and after dilution), SEK
-0,13
-0,19
-0,28
-0,34
-0,61
-0,67
Shareholder's equity per share, SEK
0,72
1,59
0,72
1,65
1,05
1,13
Average number of shares, 000'
68 475
59 265
68 475
57 023
68 465
62 739
Number of shares at closing of period, 000'
68 475
68 236
68 475
68 236
68 475
68 475
Share price at end of period, SEK
3,41
5,52
3,41
5,52
3,41
5,52
Number of sold electrodes, pieces
9 550
5 968
19 580
13 464
35 908
29 792
Average number of employees
19
17
19
17
19
17
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August 18, 2022.
This year-end report has not been subject to review by the Company’s auditors
Contact person:
Michael Colérus, CFO, +46 70 341 34 72
For more information, please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.
